Skip to content
Screener

aTyr Pharma ATYR Q2 2026 earnings

Reported August 7, 2026 · After market close

Revenue$189.6M
EPS-$0.11Beat by $0.01
EPS estimate-$0.12

Next report

Nov 5, 2026 (in 3 months)
Revenue estimate$2.5M
EPS estimate-$0.17

Financials

Q2 2026

Income statement

See full
Operating income-$10.9M+46.4%
Net income-$10.3M+47.2%
EPS (diluted)-$0.11+50.0%

Balance sheet

See full
Cash & equivalents$16.2M-6.2%
Total debt$11.8M-10.7%
Total equity$48.8M-34.8%
Total assets$69.8M-31.2%

Cash flow

See full
Operating cash flow-$9.4M+32.7%
CapEx$73.0K+711%
Free cash flow-$9.4M+32.2%

Valuation & ratios

Valuation

as of 08/11/26
See full
Market cap$50.14M-89.6%
Enterprise value$45.8M-90.4%

Returns & leverage

See full
Return on equity-98.4%+18.0pp
Debt / equity0.2×+0.1×
Current ratio5.1×-0.5×

FAQ

When did aTyr Pharma report Q2 2026 earnings?
aTyr Pharma (ATYR) reported Q2 2026 earnings on August 7, 2026 after market close.
What were aTyr Pharma's Q2 2026 revenue and EPS?
aTyr Pharma reported revenue of $189.6M and eps of $-0.11 for Q2 2026.
Did aTyr Pharma beat estimates in Q2 2026?
EPS beat the consensus estimate of $-0.12 by $0.01.
How did aTyr Pharma's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 50.0% from $-0.22.
Where can I find aTyr Pharma's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001339970-26-000051) and the 10-Q periodic report (0001339970-26-000053) directly on SEC EDGAR. The filing index links above go to sec.gov.